STOCK MARKET BSE NSE

Serum Institute seeks Modi government's nod to give 50 lakh Covishield doses to UK

This development came amid reports that the UK's anti-coronavirus inoculation programme has been hit due to a delay in the supply of the second batch of vaccines.

Published: 23rd March 2021 09:10 PM  |   Last Updated: 23rd March 2021 09:10 PM   |  A+A-

A health worker shows the Covishield vaccine, after arrival of the first batch from the Serum Institute of India at the Ahmedabad Civil Hospital.

Image used for representational purposes (Photo | EPS)

By PTI

NEW DELHI: The world's largest vaccine manufacturer by volume, Serum Institute of India, has sought permission from the Centre to supply 50 lakh doses of Oxford COVID-19 vaccine Covishield to the United Kingdom, citing an agreement with AstraZeneca in this regard.

It has, however, assured India that its own anti-coronavirus vaccination programme will not be disturbed because of this supply.

This development came amid reports that the UK's anti-coronavirus inoculation programme has been hit due to a delay in the supply of the second batch of vaccines.

In a communique to Union Health Secretary Rajesh Bhushan on Tuesday, the Director of Government and Regulatory Affairs at the Pune-based Serum Institute of India (SII), Prakash Kumar Singh, sought permission to supply 50 lakh doses of Covishield stating that India's anti-coronavirus vaccination programme will not be affected.

It referred to a license agreement between AstraZeneca UK Limited and the Serum Institute of India in June 2020 with relation to technology transfer from AZ for manufacture and supply of Covishield.

ALSO READ | AstraZeneca may have used outdated information in COVID vaccine trial: US federal health officials

"Under this agreement, it was agreed that Serum Institute of India will supply any AstraZeneca country where AstraZeneca has commitments anywhere in the world. It was further agreed that, in return for getting access to the AZ technology AZD1222, Serum Institute Of India Pvt. Ltd will treat AstraZeneca as a priority customer, whether it is for drug substance or finished product," Singh stated.

According to the agreement, Serum Institute has to supply millions of doses of Covishield to AstraZeneca according to their requirement.

"We have to supply at least 50 lakh doses to AstraZeneca immediately for use in the UK."

"This is of utmost priority as AstraZeneca has conveyed and is also reminding us of our obligation to supply Covishield to them according to the agreement. AstraZeneca and representative of the UK Government have also conveyed to us today morning that if these minimum 50 lakh doses are not supplied to the UK immediately this week then the UK government might have to halt the vaccination programme," Singh said.

The letter also reminded the government that the Serum Institute has received the technology to manufacture Covishield from AstraZeneca-Oxford and need to honour the commitment to supply at least 50 lakh doses of the vaccine.

"We are sure, considering the gravity of the situation and prestige of our company as well as our country is at stake, you will definitely intervene and give permission to us to supply at least 50 lakh doses of Covishield to the UK this week. We will be highly obliged for the same. We assure you that the Government of India's vaccination programme will not be disturbed because of this supply," Singh stated.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

edexworks
flipboard facebook twitter whatsapp